Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tirzepatide in Diabetes Mellitus, Type 2: NCT06751589 Clinical Landscape Report 2026
15 October 2026
NCT06751589 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MDG-1015 in Gastrooesophageal junction cancer: NCT06748872 Clinical Landscape Report 2026
15 October 2026
NCT06748872 clinical landscape for Gastrooesophageal junction cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
ODM-203 in Adenocarcinoma of large intestine: NCT06760702 Clinical Landscape Report 2026
15 October 2026
NCT06760702 clinical landscape for Adenocarcinoma of large intestine: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Carboplatin in Advanced Malignant Solid Neoplasm: NCT06758557 Clinical Landscape Report 2026
15 October 2026
NCT06758557 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Lenalidomide in Large B-cell lymphoma: NCT06760156 Clinical Landscape Report 2026
15 October 2026
NCT06760156 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06764017 Clinical Landscape Report 2026
15 October 2026
NCT06764017 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in High grade B-cell lymphoma: NCT06765317 Clinical Landscape Report 2026
15 October 2026
NCT06765317 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apatinib Mesylate in Endometrial Carcinoma: NCT06771154 Clinical Landscape Report 2026
15 October 2026
NCT06771154 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in Diffuse large B-cell lymphoma refractory: NCT06768905 Clinical Landscape Report 2026
15 October 2026
NCT06768905 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
HS-10502 in Advanced Malignant Solid Neoplasm: NCT06769425 Clinical Landscape Report 2026
15 October 2026
NCT06769425 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06767527 Clinical Landscape Report 2026
15 October 2026
NCT06767527 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Refractory Melanoma: NCT06771544 Clinical Landscape Report 2026
15 October 2026
NCT06771544 clinical landscape for Refractory Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.